Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff
As Supernus’ top drug inches toward the patent cliff, the central nervous system-focused drugmaker has struck an M&A deal to quickly expand its portfolio of marketed medicines. In a $ 400 million buyout, Supernus is paying $ 8.10 per share to buy CNS drugmaker Adamas Pharmaceuticals. With the deal, Supernus gets rights to Gocovri, the first and only… Read More »